Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q3 2024 CRO Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q3 2024 CRO Update

M&A activity within the Contract Research Organization (“CRO”) sector saw slightly depressed transaction volume in Q3-2024, although, a strengthening macroeconomic environment signals an uptick in Q4-2024 and the duration of 2025.

Pharmaceutical companies have long been primary clients for CROs; however, biotech and emerging pharma companies are increasingly driving market growth from a spending perspective, highlighting the evolving role of smaller, more agile players in the broader healthcare ecosystem.

The recent surge in biotech Initial Public Offerings, following a two-year slump, signals accelerated drug development efforts in the coming years. This resurgence points to increased investor confidence and a robust pipeline of research initiatives. As these companies advance, the demand for CRO services is expected to grow substantially.

To print and download the full CRO Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/10/Q3-2024-CRO-Newsletter_vP.pdf” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]